ArticleAntimicrobial agents and chemotherapy2023
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.
Open access · hybridAbstract readMulticenter Study
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Omadacycline for community-acquired infections: A systematic review and single-arm meta-analysisBiomedica : revista del Instituto Nacional de Salud · 2026Pooled it
- A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Anti-interferon-γ autoantibodies syndrome and opportunistic infections: systematic literature review.Frontiers in immunology · 2025Pooled it
- Omadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus: Results From a Phase 2, Double-blind, Randomized, Placebo-controlled Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.Clinical pharmacokinetics · 2024Trial
- Clinical Evaluation of Omadacycline for Pulmonary MycobacteriumCHEST pulmonary · 2026Article
- Beyond traditional tetracyclines: a real-world evaluation of effectiveness and safety of omadacycline therapy for complex bacterial infections.BMC infectious diseases · 2026Article
- Antibiotic dose-response curves can measure antibiotic activity againstAntimicrobial agents and chemotherapy · 2026Article
- Multicenter Real-World Outpatient Use of Intravenous Omadacycline.Infectious diseases and therapy · 2026Article
- Physical compatibility of omadacycline with intravenous agents used in the treatment of Mycobacteroides abscessus pulmonary disease.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Article
- Clinical Outcomes of Omadacycline in Critically Ill Patients Treated for Carbapenem-Resistant Organism Infections: A Retrospective Study.Infection and drug resistance · 2026Article
- Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian analysis based on the FAERS database.Frontiers in antibiotics · 2026Article
- Antibiotic dose-response curves can measure antibiotic activity againstbioRxiv : the preprint server for biology · 2025Article
- The promise and pitfalls: interpreting dual β-lactam success inASM case reports · 2025Article
- Triple antimicrobial combinations with potent synergistic activity againstAntimicrobial agents and chemotherapy · 2025Article
- New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus onAntimicrobial agents and chemotherapy · 2025Review
- Triple antimicrobial combinations with potent synergistic activity againstbioRxiv : the preprint server for biology · 2025Article
- In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline AgainstInfection and drug resistance · 2025Article
- Efficacy and safety of omadacycline for the treatment of infectious diseases: a real-world, retrospective study of 2587 patients.Frontiers in pharmacology · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 18 institutions in 1 country.
Amer El GhaliAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University , Detroit, Michigan, USA.ORCID 0000-0003-1744-0048
Taylor MorrisetteDepartment of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy , Charleston, South Carolina, USA.
Sara AlosaimyAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University , Detroit, Michigan, USA.
Kristen LucasAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University , Detroit, Michigan, USA.
Maria G Tupayachi-OrtizDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Miller School of Medicine, University of Miami , Miami, Florida, USA.
Raaga VemulaUniversity of Texas Health Science Center, University of Texas , Tyler, Texas, USA.
Carly WadleUniversity of Texas Health Science Center, University of Texas , Tyler, Texas, USA.
Julie V PhilleyUniversity of Texas Health Science Center, University of Texas , Tyler, Texas, USA.
Carlos Mejia-ChewDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
Yasir HamadDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
Ryan W StevensDepartment of Pharmacy, Mayo Clinic , Rochester, Minnesota, USA.
John D ZeuliDepartment of Pharmacy, Mayo Clinic , Rochester, Minnesota, USA.
Andrew J WebbDepartment of Pharmacy, Mayo Clinic , Rochester, Minnesota, USA.
Christina T FiskeDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Anahit SimonyanDepartment of Pharmaceutical Services, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Christo L CiminoDepartment of Pharmaceutical Services, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Mehriban MammadovaDivision of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at Houston , Houston, Texas, USA.
Virginia E UmanaDivision of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at Houston , Houston, Texas, USA.
Rodrigo HasbunDivision of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at Houston , Houston, Texas, USA.
Saira ButtDivision of Infectious Diseases, Indiana University School of Medicine , Indianapolis, Indiana, USA.
Kyle C MolinaDepartment of Emergency Medicine, University of Colorado School of Medicine , Aurora, Colorado, USA.
Michael ThomasDepartment of Emergency Medicine, University of Colorado School of Medicine , Aurora, Colorado, USA.
Emily A KaipDepartment of Pharmaceutical Services, University of California, San Francisco Medical Center , San Francisco, North Carolina, USA.
Jeannette BouchardCollege of Pharmacy, University of South Carolina , Columbia, South Carolina, USA.
Tristan W GoreCollege of Pharmacy, University of South Carolina , Columbia, South Carolina, USA.
Catessa HowardDepartment of Pharmacy, West Virginia University Medicine , Morgantown, West Virginia, USA.
M Gabriela CabanillaDivision of Infectious Diseases, University of New Mexico Health Sciences Center , Albuquerque, New Mexico, USA.
Dana J HolgerDepartment of Pharmacy Practice, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University , Fort Lauderdale, Florida, USA.
Jeremy J FrensDepartment of Pharmacy Services, Cone Health , Greensboro, North Carolina, USA.
Melissa BargerDepartment of Medicine, Ventura County Medical Center , Ventura, California, USA.
Aaron OngDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine , Baltimore, Marlyand, USA.
Keira A CohenDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine , Baltimore, Marlyand, USA.
Michael J RybakAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University , Detroit, Michigan, USA.ORCID 0000-0003-2220-0081
Eugene Applebaum College of Pharmacy and Health Sciences · USMayo Clinic · USThe University of Texas Health Science Center at Houston · USThe University of Texas Health Science Center at Tyler · USVanderbilt University Medical Center · USJohns Hopkins University · USUniversity of Colorado Denver · USUniversity of South Carolina · USWashington University in St. Louis · USCone Health · USIndiana University School of MedicineMedical University of South Carolina · USNova Southeastern University · USUniversity of California San Francisco Medical Center · USUniversity of Miami · USUniversity of New Mexico · USVentura County Medical Center · USWest Virginia University · US
Funding
Improved Tools for Nontuberculous Mycobacteria Lung DiseaseK08HL139994 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI COHEN, KEIRA ALEXIS · 2018 to 2022
$794kAnti-biofilm activity of bacteriophage-antibiotic combinations against MRSAR21AI163726 · NIAID · WAYNE STATE UNIVERSITY · PI RYBAK, MICHAEL JOSEPH · 2021 to 2022
$424kNCEZID CDC HHS U54 CK000617NHLBI NIH HHS K08 HL139994NIAID NIH HHS R21 AI163726
Abstract
Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including
Indexed as
Cystic FibrosisMycobacterium abscessusMycobacterium Infections, NontuberculousAnti-Bacterial AgentsFemaleHumansMaleNontuberculous MycobacteriaOutcome Assessment, Health CareRetrospective StudiesTetracyclinesAnti-Bacterial AgentsomadacyclineTetracyclinesculture conversionMycobacterium abscessusnontuberculous mycobacteriaomadacycline
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.